Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
58 hedge funds and large institutions have $146M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 6 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
21% more capital invested
Capital invested by funds: $121M → $146M (+$25.8M)
14% more funds holding
Funds holding: 51 → 58 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
+$5.56M |
| 2 |
D.E. Shaw & Co
New York
|
+$3.36M |
| 3 |
SCM
Saba Capital Management
New York
|
+$3.05M |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$2.18M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
-$3.07M |
| 2 |
RIA
RP Investment Advisors
Toronto,
Ontario, Canada
|
-$1.2M |
| 3 |
TI
Telemetry Investments
New York
|
-$1.01M |
| 4 |
MSU
Mizuho Securities USA
New York
|
-$559K |
| 5 |
EAM
Exos Asset Management
New York
|
-$242K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KIM
51
Karpus Investment Management
Pittsford,
New York
| $244K | – | – | – |
|
|
LCM
52
Landscape Capital Management
Englewood,
New Jersey
| $156K | +$155K | +15,967 | New |
|
|
PI
53
PEAK6 Investments
Chicago,
Illinois
| $137K | +$137K | +14,093 | New |
|
54
HighTower Advisors
Chicago,
Illinois
| $131K | +$130K | +13,400 | New |
|
|
AA
55
Ancora Advisors
Cleveland,
Ohio
| $98K | – | – | – |
|
|
VCM
56
Vivaldi Capital Management
Chicago,
Illinois
| $97K | +$96.9K | +10,000 | New |
|
57
UBS Group
Zurich,
Switzerland
| $14K | +$14.3K | +1,473 | New |
|
|
S
58
SignatureFD
Atlanta,
Georgia
| $1K | +$698 | +72 | New |
|
|
KSCM
59
Kamunting Street Capital Management
Miami Beach,
Florida
| – | -$3.07M | -317,924 | Closed |
|
|
RIA
60
RP Investment Advisors
Toronto,
Ontario, Canada
| – | -$1.2M | -124,469 | Closed |
|
|
MSU
61
Mizuho Securities USA
New York
| – | -$559K | -57,650 | Closed |
|
|
EAM
62
Exos Asset Management
New York
| – | -$242K | -25,000 | Closed |
|
|
OMC
63
Old Mission Capital
Chicago,
Illinois
| – | -$103K | -10,610 | Closed |
|
BIOT Hedge Fund Activity: Q3 2021 in Review
58 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q3 2021, worth a combined $146M — up 21% from $121M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BIOT positions and 6 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $5.56M. The largest seller was Kamunting Street Capital Management, exiting entirely with an estimated $3.07M sold.
- 58 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q3 2021, up from 51 in Q2 2021.
- Funds reported $146M of Biotech Acquisition Company Class A Ordinary Shares stock for Q3 2021, up 21% quarter-over-quarter.
- 13 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q3 2021 and 6 closed out, a net change of +7 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q3 2021 was Sage Rock Capital Management, an estimated $5.56M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q3 2021 was Kamunting Street Capital Management, an estimated $3.07M sold.
Based on aggregated 13F filings for Q3 2021.